BIM
ACRS icon

Bogle Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

Bogle Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-90,415
Closed -$668K – 275
2018
Q4 		$668K Buy
+90,415
New +$932K 0.05% 260

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Bogle Investment Management's ACRS Position: Q1 2019 in Review

Bogle Investment Management sold out of Aclaris Therapeutics (ACRS) in Q1 2019, closing a stake of 90,415 shares — an estimated $668K sold.

Bogle Investment Management first reported a position in ACRS in Q4 2018 and held it in 1 quarter. The position peaked at $668K in Q4 2018. 95 funds tracked by Wall St. Rank hold ACRS as of Q1 2019.

  • Bogle Investment Management reported no remaining Aclaris Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Bogle Investment Management sold 90,415 Aclaris Therapeutics shares in Q1 2019, an estimated $668K.
  • Bogle Investment Management first reported a position in Aclaris Therapeutics in Q4 2018 and held it in 1 quarter.
  • Bogle Investment Management's Aclaris Therapeutics position peaked at $668K in Q4 2018.
  • 95 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2019.

Based on Bogle Investment Management's 13F filing for Q1 2019, filed 13 May 2019.